Global Premenstrual Syndrome Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	158 Pages	TechNavio	January, 2024	INF18559662

Best Price Guarantee
Price	from $2,500
Length	158 Pages
Publisher	TechNavio
Published Date	January, 2024
SKU	INF18559662

Global Premenstrual Syndrome Market 2024-2028

The premenstrual syndrome market is forecasted to grow by USD 276.72 mn during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the premenstrual syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness and reporting about PMS, collaboration and partnerships among vendors, and growing preference for herbal and dietary supplements.

Technavio's premenstrual syndrome market is segmented as below:

By Drug Class

Analgesics
Oral contraceptives & ovarian suppression agents
Antidepressants
Others

By Distribution Channel

Retail pharmacies
Hospital pharmacies
Online pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the robust adoption of telemedicine as one of the prime reasons driving the premenstrual syndrome market growth during the next few years. Also, high investment on r and d on PMS drugs and menstrual health initiatives by regional governments will lead to sizable demand in the market.

The report on the premenstrual syndrome market covers the following areas:

Premenstrual syndrome market sizing
Premenstrual syndrome market forecast
Premenstrual syndrome market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premenstrual syndrome market vendors that include AbbVie Inc., Aspen Pharmacare Holdings Ltd, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, Herbalife International of America Inc., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Octavius Pharma Pvt. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Recordati S.p.A, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the premenstrual syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape; Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global premenstrual syndrome market 2018 - 2022; Exhibit 18: Historic Market Size - Data Table on global premenstrual syndrome market 2018 - 2022 ($ million); 4.2 Drug Class Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); 4.3 Distribution Channel Segment Analysis 2018 - 2022; Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); 4.4 Geography Segment Analysis 2018 - 2022; Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.5 Country Segment Analysis 2018 - 2022; Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 23: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Drug Class: 6.1 Market segments; Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%); Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%); 6.2 Comparison by Drug Class; Exhibit 32: Chart on Comparison by Drug Class; Exhibit 33: Data Table on Comparison by Drug Class; 6.3 Analgesics - Market size and forecast 2023-2028; Exhibit 34: Chart on Analgesics - Market size and forecast 2023-2028 ($ million); Exhibit 35: Data Table on Analgesics - Market size and forecast 2023-2028 ($ million); Exhibit 36: Chart on Analgesics - Year-over-year growth 2023-2028 (%); Exhibit 37: Data Table on Analgesics - Year-over-year growth 2023-2028 (%); 6.4 Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028; Exhibit 38: Chart on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million); Exhibit 39: Data Table on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million); Exhibit 40: Chart on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%); Exhibit 41: Data Table on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%); 6.5 Antidepressants - Market size and forecast 2023-2028; Exhibit 42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million); Exhibit 43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million); Exhibit 44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%); Exhibit 45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%); 6.6 Others - Market size and forecast 2023-2028; Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million); Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million); Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%); 6.7 Market opportunity by Drug Class; Exhibit 50: Market opportunity by Drug Class ($ million); Exhibit 51: Data Table on Market opportunity by Drug Class ($ million)
7 Market Segmentation by Distribution Channel: 7.1 Market segments; Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%); 7.2 Comparison by Distribution Channel; Exhibit 54: Chart on Comparison by Distribution Channel; Exhibit 55: Data Table on Comparison by Distribution Channel; 7.3 Retail pharmacies - Market size and forecast 2023-2028; Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); 7.4 Hospital pharmacies - Market size and forecast 2023-2028; Exhibit 60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibit 61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibit 62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibit 63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); 7.5 Online pharmacies - Market size and forecast 2023-2028; Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million); Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million); Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%); 7.6 Market opportunity by Distribution Channel; Exhibit 68: Market opportunity by Distribution Channel ($ million); Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Exhibit 73: Chart on Geographic comparison; Exhibit 74: Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%); Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 Germany - Market size and forecast 2023-2028; Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.9 China - Market size and forecast 2023-2028; Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%); Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%); 9.10 UK - Market size and forecast 2023-2028; Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%); 9.11 Japan - Market size and forecast 2023-2028; Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ million); Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ million); Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Exhibit 111: Market opportunity By Geographical Landscape ($ million); Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 113: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 114: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 115: Overview on factors of disruption; 11.4 Industry risks; Exhibit 116: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 117: Vendors covered; 12.2 Market positioning of vendors; Exhibit 118: Matrix on vendor position and classification; 12.3 AbbVie Inc.; Exhibit 119: AbbVie Inc. - Overview; Exhibit 120: AbbVie Inc. - Product / Service; Exhibit 121: AbbVie Inc. - Key news; Exhibit 122: AbbVie Inc. - Key offerings; 12.4 Bayer AG; Exhibit 123: Bayer AG - Overview; Exhibit 124: Bayer AG - Business segments; Exhibit 125: Bayer AG - Key news; Exhibit 126: Bayer AG - Key offerings; Exhibit 127: Bayer AG - Segment focus; 12.5 Eli Lilly and Co.; Exhibit 128: Eli Lilly and Co. - Overview; Exhibit 129: Eli Lilly and Co. - Product / Service; Exhibit 130: Eli Lilly and Co. - Key news; Exhibit 131: Eli Lilly and Co. - Key offerings; 12.6 GlaxoSmithKline Plc; Exhibit 132: GlaxoSmithKline Plc - Overview; Exhibit 133: GlaxoSmithKline Plc - Business segments; Exhibit 134: GlaxoSmithKline Plc - Key news; Exhibit 135: GlaxoSmithKline Plc - Key offerings; Exhibit 136: GlaxoSmithKline Plc - Segment focus; 12.7 Herbalife International of America Inc.; Exhibit 137: Herbalife International of America Inc. - Overview; Exhibit 138: Herbalife International of America Inc. - Product / Service; Exhibit 139: Herbalife International of America Inc. - Key offerings; 12.8 Johnson and Johnson; Exhibit 140: Johnson and Johnson - Overview; Exhibit 141: Johnson and Johnson - Business segments; Exhibit 142: Johnson and Johnson - Key news; Exhibit 143: Johnson and Johnson - Key offerings; Exhibit 144: Johnson and Johnson - Segment focus; 12.9 Lupin Ltd.; Exhibit 145: Lupin Ltd. - Overview; Exhibit 146: Lupin Ltd. - Product / Service; Exhibit 147: Lupin Ltd. - Key news; Exhibit 148: Lupin Ltd. - Key offerings; 12.10 Merck KGaA; Exhibit 149: Merck KGaA - Overview; Exhibit 150: Merck KGaA - Business segments; Exhibit 151: Merck KGaA - Key news; Exhibit 152: Merck KGaA - Key offerings; Exhibit 153: Merck KGaA - Segment focus; 12.11 Novartis AG; Exhibit 154: Novartis AG - Overview; Exhibit 155: Novartis AG - Business segments; Exhibit 156: Novartis AG - Key offerings; Exhibit 157: Novartis AG - Segment focus; 12.12 Octavius Pharma Pvt. Ltd.; Exhibit 158: Octavius Pharma Pvt. Ltd. - Overview; Exhibit 159: Octavius Pharma Pvt. Ltd. - Product / Service; Exhibit 160: Octavius Pharma Pvt. Ltd. - Key offerings; 12.13 Pfizer Inc.; Exhibit 161: Pfizer Inc. - Overview; Exhibit 162: Pfizer Inc. - Product / Service; Exhibit 163: Pfizer Inc. - Key news; Exhibit 164: Pfizer Inc. - Key offerings; 12.14 Sanofi SA; Exhibit 165: Sanofi SA - Overview; Exhibit 166: Sanofi SA - Business segments; Exhibit 167: Sanofi SA - Key news; Exhibit 168: Sanofi SA - Key offerings; Exhibit 169: Sanofi SA - Segment focus; 12.15 Sun Pharmaceutical Industries Ltd.; Exhibit 170: Sun Pharmaceutical Industries Ltd. - Overview; Exhibit 171: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibit 172: Sun Pharmaceutical Industries Ltd. - Key offerings; 12.16 Teva Pharmaceutical Industries Ltd.; Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview; Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news; Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus; 12.17 Viatris Inc.; Exhibit 178: Viatris Inc. - Overview; Exhibit 179: Viatris Inc. - Business segments; Exhibit 180: Viatris Inc. - Key news; Exhibit 181: Viatris Inc. - Key offerings; Exhibit 182: Viatris Inc. - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 183: Inclusions checklist; Exhibit 184: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 185: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 186: Research methodology; Exhibit 187: Validation techniques employed for market sizing; Exhibit 188: Information sources; 13.5 List of abbreviations; Exhibit 189: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Vendor Market Positioning; Exhibits10: Parent market; Exhibits11: Market Characteristics; Exhibits12: Offerings of vendors included in the market definition; Exhibits13: Market segments; Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits18: Historic Market Size - Data Table on global premenstrual syndrome market 2018 - 2022 ($ million); Exhibits19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million); Exhibits20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million); Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits23: Five forces analysis - Comparison between 2023 and 2028; Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits29: Chart on Market condition - Five forces 2023 and 2028; Exhibits30: Chart on Drug Class - Market share 2023-2028 (%); Exhibits31: Data Table on Drug Class - Market share 2023-2028 (%); Exhibits32: Chart on Comparison by Drug Class; Exhibits33: Data Table on Comparison by Drug Class; Exhibits34: Chart on Analgesics - Market size and forecast 2023-2028 ($ million); Exhibits35: Data Table on Analgesics - Market size and forecast 2023-2028 ($ million); Exhibits36: Chart on Analgesics - Year-over-year growth 2023-2028 (%); Exhibits37: Data Table on Analgesics - Year-over-year growth 2023-2028 (%); Exhibits38: Chart on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million); Exhibits39: Data Table on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million); Exhibits40: Chart on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%); Exhibits41: Data Table on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%); Exhibits42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million); Exhibits43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million); Exhibits44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%); Exhibits45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%); Exhibits46: Chart on Others - Market size and forecast 2023-2028 ($ million); Exhibits47: Data Table on Others - Market size and forecast 2023-2028 ($ million); Exhibits48: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits49: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits50: Market opportunity by Drug Class ($ million); Exhibits51: Data Table on Market opportunity by Drug Class ($ million); Exhibits52: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibits53: Data Table on Distribution Channel - Market share 2023-2028 (%); Exhibits54: Chart on Comparison by Distribution Channel; Exhibits55: Data Table on Comparison by Distribution Channel; Exhibits56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibits67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibits68: Market opportunity by Distribution Channel ($ million); Exhibits69: Data Table on Market opportunity by Distribution Channel ($ million); Exhibits70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits71: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits72: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits73: Chart on Geographic comparison; Exhibits74: Data Table on Geographic comparison; Exhibits75: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits76: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits77: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits78: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits79: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits80: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits81: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits82: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits83: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits84: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits85: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits86: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits91: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits92: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits93: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits94: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits99: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits100: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits101: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits102: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits103: Chart on UK - Market size and forecast 2023-2028 ($ million); Exhibits104: Data Table on UK - Market size and forecast 2023-2028 ($ million); Exhibits105: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits106: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits107: Chart on Japan - Market size and forecast 2023-2028 ($ million); Exhibits108: Data Table on Japan - Market size and forecast 2023-2028 ($ million); Exhibits109: Chart on Japan - Year-over-year growth 2023-2028 (%); Exhibits110: Data Table on Japan - Year-over-year growth 2023-2028 (%); Exhibits111: Market opportunity By Geographical Landscape ($ million); Exhibits112: Data Tables on Market opportunity By Geographical Landscape ($ million); Exhibits113: Impact of drivers and challenges in 2023 and 2028; Exhibits114: Overview on Criticality of inputs and Factors of differentiation; Exhibits115: Overview on factors of disruption; Exhibits116: Impact of key risks on business; Exhibits117: Vendors covered; Exhibits118: Matrix on vendor position and classification; Exhibits119: AbbVie Inc. - Overview; Exhibits120: AbbVie Inc. - Product / Service; Exhibits121: AbbVie Inc. - Key news; Exhibits122: AbbVie Inc. - Key offerings; Exhibits123: Bayer AG - Overview; Exhibits124: Bayer AG - Business segments; Exhibits125: Bayer AG - Key news; Exhibits126: Bayer AG - Key offerings; Exhibits127: Bayer AG - Segment focus; Exhibits128: Eli Lilly and Co. - Overview; Exhibits129: Eli Lilly and Co. - Product / Service; Exhibits130: Eli Lilly and Co. - Key news; Exhibits131: Eli Lilly and Co. - Key offerings; Exhibits132: GlaxoSmithKline Plc - Overview; Exhibits133: GlaxoSmithKline Plc - Business segments; Exhibits134: GlaxoSmithKline Plc - Key news; Exhibits135: GlaxoSmithKline Plc - Key offerings; Exhibits136: GlaxoSmithKline Plc - Segment focus; Exhibits137: Herbalife International of America Inc. - Overview; Exhibits138: Herbalife International of America Inc. - Product / Service; Exhibits139: Herbalife International of America Inc. - Key offerings; Exhibits140: Johnson and Johnson - Overview; Exhibits141: Johnson and Johnson - Business segments; Exhibits142: Johnson and Johnson - Key news; Exhibits143: Johnson and Johnson - Key offerings; Exhibits144: Johnson and Johnson - Segment focus; Exhibits145: Lupin Ltd. - Overview; Exhibits146: Lupin Ltd. - Product / Service; Exhibits147: Lupin Ltd. - Key news; Exhibits148: Lupin Ltd. - Key offerings; Exhibits149: Merck KGaA - Overview; Exhibits150: Merck KGaA - Business segments; Exhibits151: Merck KGaA - Key news; Exhibits152: Merck KGaA - Key offerings; Exhibits153: Merck KGaA - Segment focus; Exhibits154: Novartis AG - Overview; Exhibits155: Novartis AG - Business segments; Exhibits156: Novartis AG - Key offerings; Exhibits157: Novartis AG - Segment focus; Exhibits158: Octavius Pharma Pvt. Ltd. - Overview; Exhibits159: Octavius Pharma Pvt. Ltd. - Product / Service; Exhibits160: Octavius Pharma Pvt. Ltd. - Key offerings; Exhibits161: Pfizer Inc. - Overview; Exhibits162: Pfizer Inc. - Product / Service; Exhibits163: Pfizer Inc. - Key news; Exhibits164: Pfizer Inc. - Key offerings; Exhibits165: Sanofi SA - Overview; Exhibits166: Sanofi SA - Business segments; Exhibits167: Sanofi SA - Key news; Exhibits168: Sanofi SA - Key offerings; Exhibits169: Sanofi SA - Segment focus; Exhibits170: Sun Pharmaceutical Industries Ltd. - Overview; Exhibits171: Sun Pharmaceutical Industries Ltd. - Product / Service; Exhibits172: Sun Pharmaceutical Industries Ltd. - Key offerings; Exhibits173: Teva Pharmaceutical Industries Ltd. - Overview; Exhibits174: Teva Pharmaceutical Industries Ltd. - Business segments; Exhibits175: Teva Pharmaceutical Industries Ltd. - Key news; Exhibits176: Teva Pharmaceutical Industries Ltd. - Key offerings; Exhibits177: Teva Pharmaceutical Industries Ltd. - Segment focus; Exhibits178: Viatris Inc. - Overview; Exhibits179: Viatris Inc. - Business segments; Exhibits180: Viatris Inc. - Key news; Exhibits181: Viatris Inc. - Key offerings; Exhibits182: Viatris Inc. - Segment focus; Exhibits183: Inclusions checklist; Exhibits184: Exclusions checklist; Exhibits185: Currency conversion rates for US$; Exhibits186: Research methodology; Exhibits187: Validation techniques employed for market sizing; Exhibits188: Information sources; Exhibits189: List of abbreviations